Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
Frequently asked questions
What sector does Chimeric Therapeutics Limited (CHMMF) operate in?
Chimeric Therapeutics Limited belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Chimeric Therapeutics Limited (CHMMF) current stock price?
As of the latest data, Chimeric Therapeutics Limited stock price is $0.10, with a previous close of $0.10.
What is Chimeric Therapeutics Limited (CHMMF) current market capitalization?
Chimeric Therapeutics Limited market cap is approximately 14.75 million.
What is Chimeric Therapeutics Limited (CHMMF) Earnings Per Share (EPS)?
The trailing EPS is -$1.12.
What is Chimeric Therapeutics Limited (CHMMF) EBITDA?
Chimeric Therapeutics Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -4.12 million.
Does Chimeric Therapeutics Limited (CHMMF) pay dividends?
No. Chimeric Therapeutics Limited does not pay a dividend.
What is Chimeric Therapeutics Limited (CHMMF) beta (volatility) score?
Chimeric Therapeutics Limited has a beta of 0.880, meaning its volatility is roughly in line with the market.
